Advaxis Research In ActA Shows Therapeutic Anti-Cancer Response

NORTH BRUNSWICK, N.J.--(EON: Enhanced Online News)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has published new research findings on ActA as a potential, anti-cancer component and a new complement to the Company’s evolving proprietary Listeria technology platform.

“Listeria-Derived ActA Is An Effective Adjuvant for Primary and Metastatic Tumor Immunotherapy.”

In collaborative research out of the laboratories of Advaxis and the company’s scientific founder, Dr. Yvonne Paterson, at the University of Pennsylvania, it was found that ActA, either fused to an antigen and delivered with a live, attenuated Listeria vaccine or as a mixture with an antigen and not secreted by Listeria, resulted in a therapeutic immune response against TC-1 tumor cells. Moreover, it was found that the adjuvant actions of ActA stimulated immunity in the presence of immune tolerance, enabling a therapeutic response in animals whose immune systems were fatigued and ineffective against the target antigen.

For further details, these findings can be found in the scientific journal, “Cancer Immunology and Immunotherapy” in a soon to be published research paper titled, “Listeria-Derived ActA Is An Effective Adjuvant for Primary and Metastatic Tumor Immunotherapy.” The current online version can be found on Pubmed.Gov.

About ActA and Advaxis, Inc.

In February 2010 the US Patent and Trademark Office (USPTO) granted Advaxis two (2) ActA-specific patents i.e., the use of ActA as an immune adjuvant, either fused or in combination with an antigen. These patents extended the Company’s proprietary technology to include two (2) families of antigen-adjuvant fusion proteins based on listeriolysin O (LLO) or ActA. Advaxis is currently developing vaccines using ActA.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.

Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.